监管性T细胞疗法市场－全球产业规模、份额、趋势、机会及预测（按类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球调节性 T 细胞 (Treg) 疗法市场预计将从 2025 年的 27.7 亿美元成长到 2031 年的 227.5 亿美元，复合年增长率高达 42.04%。

这些治疗方法是免疫调节疗法，利用特定的CD4+ T细胞亚群来抑制过度免疫反应，主要用于治疗自体免疫疾病和移植物抗宿主疾病。该市场的成长主要受全球自体免疫疾病发病率上升以及基于细胞的免疫耐受重建机制所蕴含的巨大临床潜力的驱动。业界积极的研发活动也进一步推动了这一成长动能。根据国际细胞与基因治疗学会（ISCT）预测，到2024年下半年，全球在研细胞和基因疗法将达到3063种，显示市场拥有强劲的投资环境，有利于推动这些疗法的进步。

儘管呈现正面趋势，但市场仍面临与生产扩充性和复杂性相关的重大障碍。分离、纯化和扩增稳定的Treg细胞群所需的复杂流程，导致生产成本高且技术变异性大。这些物流方面的挑战构成重大障碍，可能延缓Treg细胞的广泛商业化进程，并限制患者获得这些先进治疗方法。

市场驱动因素

推动Treg市场发展的关键因素是创业投资和政府资金的涌入，这为支付临床试验和生产的高昂成本提供了必要的流动资金。主要产业参与者纷纷获得大量资金以推进自体免疫疾病治疗研发管线，充分证明了这些复杂治疗方法的商业性可行性，也印证了这项资金成长动能。例如，Kyverna Therapeutics在2024年2月的新闻稿中宣布，在完成首次股票公开发行（IPO）后，该公司已成功资金筹措3.669亿美元，用于支持其基因修饰细胞疗法的研发。此类成功案例显示投资者信心正在全面復苏。根据再生医学联盟（Alliance for Regenerative Medicine）报告，光是2024年第一季，全球细胞和基因治疗领域就吸引了44亿美元的投资，显示Treg等新型治疗方法拥有充足的资金支持。

同时，在干细胞和实体器官移植中移植物抗宿主疾病（GVHD）发生率的上升，推动了对标靶诱导免疫耐受疗法的需求。随着骨髓恶性肿瘤移植数量的增加，传统全身性免疫抑制剂的限制促使人们寻求精确的Treg製剂以恢復免疫稳态。根据美国癌症协会2024年1月发布的《2024年癌症事实与数据》报告，美国预计将新增62,770例白血病病例，这将形成一个可能需要造血干细胞移植并面临高GVHD风险的患者群体。这种临床负担迫切需要开发能够在不损害全身免疫的情况下预防移植物排斥的Treg疗法，使其成为移植医学领域未来重要的替代疗法。

市场挑战

全球调节性T细胞（Treg）疗法市场成长面临的核心挑战之一是生产过程的复杂性和规模化难度。与标准生物製药不同，Treg疗法需要分离和扩增稀有且具有活性的细胞亚群，这些细胞必须在整个生产週期内保持表型稳定性和抑制功能。这一复杂过程极易受到技术因素的影响，导致产量不稳定和销售成本高。因此，这些物流障碍使得研发人员难以将临床疗效转化为商业性可行的规模化生产，限制了市场渗透率和病患可近性。

这种规模化瓶颈导致商业性成功高度集中，只有少数治疗方法能够克服产业化障碍。生产规模化的高失败率阻碍了大量候选药物上市。例如，再生医学联盟指出，到2025年，全球先进疗法领域约75%的收入将来自少于10种产品。这项数据凸显了研发活动与商业性现实之间的严重脱节，其主要原因是无法有效率地大规模生产Treg等复杂的细胞疗法。

市场趋势

利用嵌合体抗原受体 (CAR) 技术进行精准标标靶化正在革新市场。该技术能够建构多克隆抗体Treg 更具特异性的工程化 Treg 细胞，从而满足了在不产生传统治疗方法固有的广泛免疫抑制的情况下，有效抑制致病性免疫反应的关键需求。研发人员正利用这项技术来验证其在 B 细胞介导的自体免疫疾病中持久的临床疗效。例如，Kyverna Therapeutics 在 2024 年 11 月的新闻稿中宣布，四名接受其 CAR-Tr​​eg 疗法 KYV-101 治疗的狼疮性肾炎患者在至少六个月的随访期内实现了持续的疾病控制，证实了这种精准疗法的持久疗效。

同时，製药公司和生技公司之间透过合作授权协议进行研发的策略整合，正推动早期候选药物快速转化为临床应用。大型製药企业越来越多地与专业生物技术公司合作，以获取专有的Treg平台技术，从而降低细胞疗法复杂生产和开发过程中的风险。这一趋势使得规模较小的开发商能够利用成熟公司的监管应对力和工业规模来推进其研发管线。 Quell Therapeutics在2024年11月的新闻稿中宣布，该公司在与阿斯特捷利康合作的1型糖尿病项目中成功选定领先候选药物后，接受了1000万美元的付款，这凸显了此类战略合作的价值，也体现了这一趋势。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球调节性T细胞（Tregs）疗法市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（自体移植、异体移植）
  • 依应用领域（自体免疫疾病、器官移植、移植物抗宿主疾病（GVHD）等）
  • 依最终使用者（医院/诊所、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美调节性T细胞（Tregs）疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲监管T细胞（Tregs）疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区调节性T细胞（Tregs）疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲调节性T细胞（Tregs）疗法的市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲调节性T细胞（Tregs）疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球调节性T细胞（Tregs）疗法市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abata Therapeutics
• Atara Biotherapeutics Inc
• Bastion Therapeutics
• Cellenkos, Inc.
• Coya Therapeutics, Inc.
• GentiBio Inc
• Kyverna Therapeutics Inc
• PolTREG SA
• TeraImmune, Inc
• Tr1X TRACT Therapeutics, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Regulatory T-cells (Tregs) Therapies Market is projected to experience substantial growth, expanding from a valuation of USD 2.77 Billion in 2025 to USD 22.75 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 42.04%. These therapies involve immunomodulatory treatments using a specialized subset of CD4+ T cells designed to suppress excessive immune reactions, with a primary focus on treating autoimmune diseases and graft-versus-host disease. The market is fundamentally propelled by the increasing global prevalence of autoimmune disorders and the significant clinical promise of cell-based mechanisms to re-establish immune tolerance. This momentum is further supported by extensive developmental activity within the sector; according to the International Society for Cell & Gene Therapy, the global pipeline included 3,063 cell and gene therapies in the second half of 2024, indicating a robust investment environment driving these advancements.

Despite this positive trajectory, the market confronts a major obstacle regarding manufacturing scalability and complexity. The intricate procedures required to isolate, purify, and expand stable Treg populations entail high production costs and technical variability. These logistical hurdles create significant barriers that could delay widespread commercialization and restrict patient access to these advanced therapies.

Market Driver

A primary catalyst for the advancement of the Treg market is the influx of venture capital and government funding, which provides the necessary liquidity to navigate high clinical trial and manufacturing costs. This financial momentum is illustrated by major industry players securing significant capital to progress their autoimmune pipelines, confirming the commercial viability of these complex therapies. For instance, Kyverna Therapeutics announced in a February 2024 press release regarding the closing of its upsized initial public offering that it successfully raised gross proceeds of $366.9 million to support its engineered cell therapy development. Such corporate successes indicate a broader resurgence in investor confidence, as highlighted by the Alliance for Regenerative Medicine, which reported that the global cell and gene therapy sector attracted $4.4 billion in investment during the first quarter of 2024 alone, demonstrating the deep financial resources available for novel modalities like Tregs.

In parallel, the rising incidence of Graft-Versus-Host Disease (GVHD) in stem cell and organ transplantation is intensifying the demand for targeted tolerance-inducing therapies. As transplant volumes increase to treat blood malignancies, the limitations of traditional systemic immunosuppressants represent a driver for the search for precise Treg formulations capable of restoring immune homeostasis. According to the American Cancer Society's "Cancer Facts & Figures 2024" report from January 2024, there were an estimated 62,770 new leukemia cases in the United States, representing a significant patient population potentially requiring hematopoietic stem cell transplantation and facing high GVHD risks. This clinical burden necessitates the development of Treg therapies that prevent graft rejection without compromising general immunity, positioning them as critical future alternatives in transplant care.

Market Challenge

The central challenge impeding the growth of the Global Regulatory T-cells (Tregs) Therapies Market is the profound difficulty associated with manufacturing complexity and scalability. Unlike standard biologics, Treg therapies require the isolation and expansion of a rare, living cellular subset that must maintain phenotypic stability and suppressive function throughout the production cycle. This complex process is subject to technical variability, leading to inconsistent yields and exorbitant Cost of Goods Sold (COGS). Consequently, these logistical barriers make it incredibly difficult for developers to transition from clinical efficacy to commercially viable mass production, thereby limiting market penetration and patient access.

This scalability bottleneck has created a landscape where commercial success remains highly concentrated, as few therapies can successfully overcome the industrialization barrier. The high failure rate in scaling production prevents the vast pipeline of candidates from reaching the market. For example, the Alliance for Regenerative Medicine noted that in 2025, approximately 75 percent of global revenue in the advanced therapy sector was derived from fewer than 10 products. This statistic underscores the severe disconnect between developmental activity and commercial reality, driven largely by the inability to efficiently manufacture complex cell-based therapies like Tregs at scale.

Market Trends

The integration of Chimeric Antigen Receptor (CAR) technology for precision targeting is fundamentally reshaping the market by enabling the creation of engineered Tregs with specificity that exceeds that of polyclonal counterparts. This shift addresses the critical need for potent suppression of pathogenic immune responses without causing broad immunosuppression, a limitation inherent in earlier modalities. Developers are successfully leveraging this technology to demonstrate durable clinical efficacy in B-cell driven autoimmune conditions; for instance, Kyverna Therapeutics announced in a November 2024 press release that four patients with lupus nephritis treated with the CAR-Treg therapy KYV-101 achieved sustained disease control with at least six months of follow-up, validating the therapeutic endurance of this precision approach.

Simultaneously, the strategic consolidation of R&D through collaborative licensing between pharmaceutical companies and biotech firms is accelerating the translation of early-stage candidates into clinical reality. Large pharmaceutical entities are increasingly partnering with specialized biotech firms to access proprietary Treg platforms, thereby mitigating the risks associated with the complex manufacturing and development of cell therapies. This trend allows smaller developers to leverage the regulatory and industrial scale of established players to advance their pipelines. Highlighting this, Quell Therapeutics announced in a November 2024 press release that it received a $10 million payment from AstraZeneca after successfully selecting a lead candidate for their joint Type 1 Diabetes program, underscoring the value placed on these strategic alliances.

Key Market Players

• Abata Therapeutics
• Atara Biotherapeutics Inc
• Bastion Therapeutics
• Cellenkos, Inc.
• Coya Therapeutics, Inc.
• GentiBio Inc
• Kyverna Therapeutics Inc
• PolTREG S.A.
• TeraImmune, Inc
• Tr1X TRACT Therapeutics, Inc

Report Scope

In this report, the Global Regulatory T-cells (Tregs) Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Regulatory T-cells (Tregs) Therapies Market, By Type

• Autologous
• Allogenic

Regulatory T-cells (Tregs) Therapies Market, By Applications

• Autoimmune Diseases
• Organ Transplantation
• Graft-versus-Host Disease (GVHD)
• Others

Regulatory T-cells (Tregs) Therapies Market, By End-User

• Hospitals & Clinics
• Academic & Research Institutions
• Others

Regulatory T-cells (Tregs) Therapies Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Regulatory T-cells (Tregs) Therapies Market.

Available Customizations:

Global Regulatory T-cells (Tregs) Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Regulatory T-cells (Tregs) Therapies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Autologous, Allogenic)
  • 5.2.2. By Applications (Autoimmune Diseases, Organ Transplantation, Graft-versus-Host Disease (GVHD), Others)
  • 5.2.3. By End-User (Hospitals & Clinics, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Regulatory T-cells (Tregs) Therapies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Applications
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Regulatory T-cells (Tregs) Therapies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Applications
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Regulatory T-cells (Tregs) Therapies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Applications
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Regulatory T-cells (Tregs) Therapies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Applications
      • 6.3.3.2.3. By End-User

7. Europe Regulatory T-cells (Tregs) Therapies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Applications
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Applications
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Applications
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Applications
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Applications
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Regulatory T-cells (Tregs) Therapies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Applications
      • 7.3.5.2.3. By End-User

8. Asia Pacific Regulatory T-cells (Tregs) Therapies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Applications
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Applications
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Applications
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Applications
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Applications
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Regulatory T-cells (Tregs) Therapies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Applications
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Regulatory T-cells (Tregs) Therapies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Applications
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Regulatory T-cells (Tregs) Therapies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Applications
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Regulatory T-cells (Tregs) Therapies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Applications
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Regulatory T-cells (Tregs) Therapies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Applications
      • 9.3.3.2.3. By End-User

10. South America Regulatory T-cells (Tregs) Therapies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Applications
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Regulatory T-cells (Tregs) Therapies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Applications
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Regulatory T-cells (Tregs) Therapies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Applications
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Regulatory T-cells (Tregs) Therapies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Applications
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Regulatory T-cells (Tregs) Therapies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abata Therapeutics
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Atara Biotherapeutics Inc
• 15.3. Bastion Therapeutics
• 15.4. Cellenkos, Inc.
• 15.5. Coya Therapeutics, Inc.
• 15.6. GentiBio Inc
• 15.7. Kyverna Therapeutics Inc
• 15.8. PolTREG S.A.
• 15.9. TeraImmune, Inc
• 15.10. Tr1X TRACT Therapeutics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer